Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Counting The Cost Of Delay For Revlimid Front-line Myeloma Approval

Executive Summary

Fear of second primary cancers foils Celgene’s filing of Revlimid for front-line/maintenance myeloma in Europe. Meanwhile, debate continues about the clinical value and high cost of prolonged treatment, and new options for relapse patients emerge, notably Onyx’s Kyprolis and Celgene’s pomalidomide.


Related Content

Celgene Secures Revlimid Frontline Myeloma Approval
Celgene Has A Swift Start For Pomalyst Launch
Onyx’s Kyprolis Sails Through FDA Panel, Boosted By Confirmatory Trial Plans
Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach
Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts